David A. Weber, Ph.D.
Chief Executive Officer, President and Board Member
David A. Weber, Ph.D. has served as our President and Chief Executive Officer and on our board of directors since November 2010. Prior to joining us, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting Chief Executive Officer and Executive Vice President of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber received his Ph.D. in medical microbiology from Creighton University and his Master’s and Bachelor’s degrees in biological sciences from Wichita State University.
Kathie M. Bishop, Ph.D.
Chief Scientific Officer
Kathie M. Bishop, Ph.D., was appointed as our Chief Scientific Officer in November 2016 and joined the company beginning in January 2017. Dr. Bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience. Prior to Otonomy she served as Chief Scientific Officer of Tioga Pharmaceuticals from May 2015 to November 2016. From September 2009 to April 2015, she served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translational research and development of multiple preclinical and clinical programs in the neurology franchise including SPINRAZA™ (nusinersen), an approved treatment for patients with spinal muscular atrophy that was awarded the Prix Galien USA Award for the Best Biotechnology Product in 2017. From August 2001 to September 2009, Dr. Bishop served in research and development leadership roles at Ceregene, a company focused on the development of gene therapy products for the treatment of neurodegenerative disorders and retinal diseases. From September 1997 to July 2001, she worked as a post-doctoral fellow in the Molecular Neurobiology Lab at the Salk Institute for Biological Studies. Dr. Bishop obtained a Ph.D. in Neuroscience from the University of Alberta and Bachelor’s degrees in Cell Biology and Genetics from the University of British Columbia and Psychology from Simon Fraser University.
Paul E. Cayer
Chief Financial & Business Officer
Paul E. Cayer has served as our Chief Business Officer since October 2008 and Chief Financial Officer since October 2010. Mr. Cayer brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as Senior Vice President, Corporate Development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. From 2001 to 2005, Mr. Cayer served as the Chief Financial Officer and Senior Vice President, Business Development of Targeted Molecules Corporation, a biopharmaceutical company. Mr. Cayer has also held various management positions with Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company, and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his MBA and Bachelor’s degree in biomechanical engineering from Harvard University.
Dean Hakanson, M.D.
Chief Medical Officer
Dean Hakanson, M.D. has served as our Chief Medical Officer since April 2015. From May 2010 to March 2015, Dr. Hakanson served as Vice President and Head of Health Economics and Outcomes Research for U.S. Medical and Regulatory Affairs, and from July 2009 to May 2010 as Vice President and Medical Head of the Western U.S. Operating Unit, for Novartis AG, a pharmaceutical company. From January 2008 to July 2009, Dr. Hakanson served as Vice President of Healthcare Access for Bristol-Myers Squibb Company, a manufacturer of prescription pharmaceuticals. From June 2005 to January 2008, Dr. Hakanson served as Head of Value-Based Health Care/Payer Field Team for Genentech, Inc., a biotechnology corporation which is now a division of F. Hoffman-La Roche AG. From 1998 to 2005, he held various positions at GlaxoSmithKline plc, a pharmaceutical and consumer healthcare company, which included Vice President, Medical Affairs Commercial Operations and Vice President of Managed Markets, National Accounts. Earlier in his career he practiced clinical medicine in critical care at John C. Lincoln IDS and Tenet Healthcare Corporation. He is also a Fellow with the American Academy of Otolaryngology – Head and Neck Surgery and a Diplomat of the American Board of Anesthesiology, American Medical Association and the American Association for Physician Leadership. Currently he has an active license to practice medicine in California and Arizona. Dr. Hakanson received his Bachelor’s degree in cellular physiology and physics from the University of Denver, a Medical degree from the University of Colorado School of Medicine, anesthesiology residency training at the University of Michigan and training in critical care at the University of California, Davis Medical Center.
General Counsel and Chief Compliance Officer
Eric Loumeau has served as our General Counsel and Chief Compliance Officer since May 2015 and Secretary since July 2015. Mr. Loumeau brings over 23 years of experience as in-house legal counsel and compliance officer for several biopharmaceutical companies and as outside corporate counsel supporting healthcare and technology based client companies. Prior to joining our company, Mr. Loumeau was the Vice President of Legal Affairs at The Medicines Company from December 2013 to May 2015, a role he held following the company's acquisition of Rempex Pharmaceuticals. From June 2011 to December 2013 Mr. Loumeau served as Vice President, Chief Financial Officer and Chief Compliance Officer of Rempex Pharmaceuticals. From January 2009 to January 2011 he was Partner at Bass, Berry & Sims, PLC, and from May 2007 to January 2009 he was Partner at Mintz Levin Cohn Ferris Glovsky and Popeo PC. From October 1999 to May 2007, Mr. Loumeau served as General Counsel and Chief Compliance Officer for Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company. Prior to this role he was Partner and Associate at Cooley LLP from April 1995 to October 1999, and an Associate at Skadden, Arps, Slate, Meagher & Flom LLP, from September 1991 to April 1995. Mr. Loumeau obtained a Juris doctorate from Boalt Hall School of Law at the University of California, Berkeley, including spending his final year at Harvard Law School through the Harvard-Boalt Exchange Program. He obtained a Bachelor's degree in finance from Brigham Young University.
Robert Michael Savel, II
Chief Technical Officer
Robert Michael Savel, II has served as our Chief Technical Officer since January 2014. From September 2011 to December 2013, Mr. Savel served as General Manager and Senior Vice President of Operations for Optimer Pharmaceuticals, Inc., a biopharmaceuticals company. From September 2010 to June 2011, Mr. Savel served as Senior Vice President and Chief Technical Officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From April 2008 to September 2010, Mr. Savel served as President of Savel Enterprises LLC, a management consulting firm. From April 2007 to April 2008, Mr. Savel served as the Senior Vice President of Technical Operations for PDL BioPharma, an antibody manufacturer. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods manufacturer, which included the position of Vice President, Quality and Compliance. Mr. Savel received his Bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.